Bone · Research Phase
Osteogenic Growth Peptide (OGP)
No lawful US pathway
01 · Overview
Osteogenic growth peptide is a naturally occurring 14-amino acid peptide identified in serum that has been studied for its effects on osteoblast proliferation and differentiation. Shorter fragments, in particular the C-terminal pentapeptide, and synthetic analogs have been developed in an attempt to improve stability and activity.
Research applications include osteoporosis, fracture healing and functionalized implant surfaces. All of this work is preclinical.
02 · Research summary & key findings
In ovariectomized rats, the osteogenic growth peptide C-terminal pentapeptide and its analog partially inhibited bone loss, and the pentapeptide combined with risedronate produced notably increased bone mineral density at the whole femur, distal metaphysis and lumbar spine along with higher bending energy and serum osteocalcin and IGF-2 than the other groups (PMID 36874360). These findings come from a rodent osteoporosis model rather than from human studies. No clinical trials in humans were identified, and the peptide remains in preclinical development.
03 · Regulatory status
Osteogenic Growth Peptide (OGP) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Osteogenic Growth Peptide (OGP) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 8 FDA-approved compounds in Bone
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
Osteogenic Growth Peptide (OGP) is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Effects of osteogenic growth peptide C-terminal pentapeptide and its analogue on bone remodeling in an osteoporosis rat model Open Med (Wars), 2023. PMID 36874360
Primary literature
- PubMed: "Osteogenic Growth Peptide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Osteogenic Growth Peptide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Osteogenic Growth Peptide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Bone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.